CLN3 Polyclonal Antibody

Catalog No	BYab-07341
Isotype	IgG
Reactivity	Human;Rat;Mouse;
Applications	WB;ELISA
Gene Name	CLN3 BTS
Protein Name	Battenin (Batten disease protein) (Protein CLN3)
Immunogen	Synthesized peptide derived from human protein . at AA range: 221-270
Specificity	CLN3 Polyclonal Antibody detects endogenous levels of protein.
Formulation	Liquid in PBS containing 50% glycerol, and 0.02% sodium azide.
Source	Polyclonal, Rabbit,IgG
Purification	The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Dilution	WB 1:500-2000 ELISA 1:5000-20000
Concentration	1 mg/ml
Purity	≥90%
Storage Stability	-20°C/1 year
Synonyms	
Observed Band	48kD
Cell Pathway	Lysosome membrane ; Multi-pass membrane protein . Late endosome . Lysosome . Golgi apparatus . Golgi apparatus membrane . Golgi apparatus, Golgi stack . Golgi apparatus, trans-Golgi network . Cell membrane . Recycling endosome . Membrane raft . Membrane, caveola . Early endosome membrane . Cell junction, synapse, synaptosome . Late endosome membrane . Cytoplasmic vesicle, autophagosome . CLN3 is not present in late endosomes/lysosomes in fibroblasts and neurons (PubMed:15240864). Trafficks from cell membrane to Golgi via endosomes (PubMed:15240864). Osmotic stress changes the subcellular localization of CLN3 (PubMed:23840424). Trafficks to intracellular compartments via the plasma membranet through AP3M1-dependent mechanisms (PubMed:14644441). Excluded from the synaptic vesicles (By simila
Tissue Specificity	Expressed in the cortical brain, pancreas, spleen, and testis with weaker expression in the peripheral nerve (at protein level). Highly expressed in gray matter (at protein level).
Function	alternative products:Additional isoforms seem to exist,disease:Defects in CLN3

	are the cause of Batten disease [MIM:204200]; also known as juvenile-onset ceroid lipofuscinosis neuronal type 3 (CLN3). Batten disease is a recessively inherited neurodegenerative disorder of childhood characterized by progressive loss of vision, seizures, and psychomotor disturbances. Biochemically, the disease is characterized by lysosomal accumulation of hydrophobic material, mainly ATP synthase subunit C. Clinical onset is usually from 5 to 10 years of age. No treatment is available and Batten disease is usually fatal within a decade. The incidence is estimated at 1/20000 to 1/100000 live birth, making it one of the most common neurodegenerative diseases of childhood.,online information:Neural Ceroid Lipofuscinoses mutation db,online information:Retina International's Scientific Newsletter,PTM:Highly glyc
Background	This gene encodes a protein that is involved in lysosomal function. Mutations in this, as well as other neuronal ceroid-lipofuscinosis (CLN) genes, cause neurodegenerative diseases commonly known as Batten disease or collectively known as neuronal ceroid lipofuscinoses (NCLs). Many alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Jul 2008],
matters needing attention	Avoid repeated freezing and thawing!
Usage suggestions	This product can be used in immunological reaction related experiments. For more information, please consult technical personnel.

Products Images